Tobias F Dreyer

6PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer geneticsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 24, 2026
High uPAR and Low miR-221 Expression Predict Poor Disease-Free Survival in Triple-Negative Breast Cancer.

|Jan 10, 2026
Drug Discovery Strategies for Kallikrein-Related Peptidases.

Tobias Dreyer, Daniela Schuster, Viktor Magdolen

|Oct 30, 2024
Expert-Guided Large Language Models for Clinical Decision Support in Precision Oncology.

Jacqueline Lammert, Tobias Dreyer, Sonja Mathes

|Oct 27, 2022
A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression.

Yueyang Liu, Weiwei Gong, Sarah Preis

|Apr 28, 2021
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer In Vitro and In Vivo.

Tobias F Dreyer, Sabine Kuhn, Christoph Stange

|Dec 01, 2020
KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.

Brian W-C Tse, Thomas Kryza, Mei-Chun Yeh

Pageof 1

Frequent Collaborators

5 joint publications

Viktor Magdolen

4 joint publications

Marion Kiechle

1 joint publications

Brian W-C Tse

1 joint publications

Thomas Kryza